Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc > my last post

<< Previous

Bullboard Posts

Next >>

Comment by Strodon Oct 27, 2010 11:00am

310 Views

Post# 17618181

RE: RE: RE: my last post

Uranium juniors definitely seem to be showing signs of life from silly undervalued prices. With such a unique property and soon to be cashed up, there seems to be a great risk/reward that this junior pops to the 0.30s once the financing is closed and the drill start turning.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security